Allogenic mesendritic vector for ovarian cancer
AssigneeSubhadra Dravida
InventorSUBHADRA DRAVIDA
Life of this patent
Estimating the term…
Abstract
The present invention recommends a new approach of allogenic dendritic-stem cell vaccine platform to treat all kinds of ovarian cancers. It proposes the abundant allogenic donated cord blood source to harvest both dendritic special type and mesenchymal stem cells equilibrated package primed with patient's tumour antigens for a targeted treatment regime. The individual roles of dendritic cells and mesenchymal stem cells in immunomodulation is exploited in developing this new combinatorial platform of cellular vectors for targeted killing of tumour cells in the patient's body. The source proposed here in developing the technology is a biological discard and is available in profusion for proposed clinical application.
Claims9
A method of preparing a novel pharmaco-cellular composition to be administered into the patient's body as vector for treating solid tumors comprising the steps of:
- a. collecting blood sample from an allogenic donor in a sterile collection bag;
- b. preparing stable, viable, expressive and differentiable mesenchymal stem cells;
- c. preparing stable dendritic cells from the collected blood sample;
- d. mixing the mesenchymal stem cells and the dendritic cells at a pre-determined ratio to form a cell based vector;
- and
- e. mixing the said cell based vector with a pre-determined quantity of isolated autologous tumor cells essentially containing tumor cell antigen at specific condition.
A novel pharmaco-cellular composition to be administered in to the patient's body as vector for treating solid tumors as immediately as possible without any delay as in autologous preparation, primarily comprising of allogenic stable and expressive mesenchymal stem cells and allogenic special type dendritic cells in equilibrated package, primed with autologous patient's tumour antigens for a targeted treatment regime.
Dependencies are inferred from the claim text.